Fact-checked by Grok 2 weeks ago

Somnolence

Somnolence, commonly referred to as drowsiness or , is a state of strong desire for or feeling unusually sleepy during waking hours, often leading to unintended naps or impaired . A 2025 survey by the found that 72% of adults experience daytime sleepiness affecting their daily activities. It differs from normal by involving a propensity to fall asleep involuntarily, which can compromise safety in activities like or operating machinery. This condition frequently arises from disruptions in sleep quantity or quality, such as or irregular schedules like , as well as medical conditions, sedating medications, and primary sleep disorders. For example, and —where excessive sleepiness persists despite adequate sleep opportunities—are common contributors. Symptoms extend beyond tiredness and may include difficulty concentrating, slowed reaction times, yawning, and unintentional lapses into sleep. Persistent somnolence impacts daily functioning, increasing accident risks and reducing . Recent 2025 research links it to cardiovascular risks, mood disorders, cognitive decline, and heightened postoperative cognitive problems. Diagnosis involves medical history, sleep diaries, the , and possibly . Treatment addresses underlying causes, such as CPAP for , sleep hygiene improvements, medication adjustments, or stimulants like . Early intervention is crucial, with 2025 studies identifying blood molecules associated with for potential future diagnostics.

Overview

Definition

Somnolence is defined as a state of drowsiness or excessive sleepiness, characterized by a strong desire to fall asleep or an inclination to sleep for unusually long periods. This condition manifests as a transient urge to sleep that can occur in various situations, often without indicating a , and may lead to unintended dozing off during wakeful activities. Unlike mere tiredness, somnolence specifically involves an impaired state that compromises and cognitive function. The term "somnolence" originates from the Latin word , meaning "," and entered English usage in the through medical and . Historically, it was first recognized in medical contexts during descriptions of and profound drowsiness observed in patients with infectious diseases, such as those exhibiting pathological sleepiness in the . Somnolence is distinct from , which refers to a sense of mental or physical exhaustion and low without the specific to sleep or the associated disruption in normal mechanisms. In contrast to —a chronic disorder marked by and prolonged nighttime sleep despite sufficient rest—somnolence typically presents as a symptomatic state rather than a persistent pathological condition.

Physiology

Somnolence, or , arises from the interplay of circadian and homeostatic processes that regulate the sleep-wake cycle. The (SCN) in the serves as the primary circadian pacemaker, synchronizing physiological rhythms to the 24-hour light-dark cycle. This nucleus receives direct input from retinal ganglion cells via the , enabling it to entrain internal clocks to environmental light cues. Through neural projections and hormonal signals, the SCN modulates sleep propensity by influencing the release of from the , which peaks at night to promote sleepiness, and from the adrenal glands, which surges in the morning to enhance . Neurotransmitters play a critical role in modulating and sleepiness. , a of ATP metabolism, accumulates in the and other brain regions during prolonged , acting on and receptors to inhibit wake-promoting and histaminergic neurons, thereby increasing sleep pressure. In contrast, (also known as hypocretin), produced by neurons in the , stabilizes by exciting arousal centers throughout the , , and ; reduced signaling leads to fragmented wake states and heightened somnolence vulnerability. The homeostatic drive for sleep, often termed Process S, builds progressively with time awake, reflecting the need for restorative , and interacts with the circadian Process C to determine overall sleepiness levels. This two-process model, proposed by Borbély, posits that Process S increases exponentially during wakefulness due to factors like buildup, while Process C provides a sinusoidal modulation peaking in alertness during the day and sleepiness at night. At the neural level, sleep-promoting and galaninergic neurons in the (VLPO) activate during sleep onset, reciprocally inhibiting key arousal nuclei such as the (histamine), locus coeruleus (norepinephrine), and dorsal raphe (serotonin) in the and , facilitating the transition to somnolent states.

Causes

Circadian and Sleep Disorders

disorders involve misalignment between an individual's internal and the external 24-hour day-night cycle, leading to somnolence through chronic sleep-wake disruptions. These disorders prevent adequate restorative , resulting in that impairs daily functioning. arises from working non-standard hours, such as night or rotating shifts, which desynchronizes the from environmental cues like . This misalignment causes during intended sleep periods and excessive sleepiness during work hours, affecting up to 10-40% of shift workers depending on schedule demands. The condition manifests as persistent and reduced , with symptoms worsening over prolonged exposure to irregular schedules. Delayed sleep phase syndrome (DSPS), also known as delayed sleep-wake phase disorder, features a delayed where sleep onset and offset are shifted later by two or more hours compared to conventional times. Individuals typically cannot fall asleep before 2-6 a.m. and prefer waking in the late morning or afternoon, leading to sleep deprivation when societal obligations force earlier rising and resultant daytime somnolence. This disorder often begins in and contributes to chronic , exacerbating difficulties in concentration and mood regulation. In contrast, advanced sleep phase syndrome (ASPS) involves an advanced , with sleepiness onset as early as 6-9 p.m. and spontaneous awakening between 2-5 a.m. This premature timing disrupts alignment with typical social and work schedules, causing early morning and compensatory daytime or sleepiness if individuals attempt to extend . ASPS is less common than DSPS and often emerges in , linked to genetic factors in familial cases, resulting in persistent deficits during conventional daytime hours. Non-24-hour sleep-wake disorder occurs when the endogenous circadian period exceeds 24 hours, preventing stable entrainment to the daily light-dark cycle, and is particularly prevalent among totally blind individuals lacking light perception for synchronization. The sleep-wake cycle progressively shifts later each day by minutes to hours, leading to alternating periods of relative alignment (normal sleep), misalignment causing at desired bedtime, and hypersomnolence during desired wake times over several weeks, with accumulated . In sighted individuals, it is rare but follows similar progressive desynchronization, often triggered by neurological factors. Primary sleep disorders also contribute to somnolence by fragmenting nocturnal or directly impairing wake-promoting mechanisms. , characterized by difficulty initiating or maintaining , leads to chronic and resultant daytime somnolence through accumulated and impaired sleep quality. (OSA) involves repeated upper airway collapses during , causing intermittent and arousals that fragment sleep architecture without full awakenings. This non-restorative results in profound daytime somnolence, with affected individuals experiencing uncontrollable sleepiness that increases accident risk. is high, affecting 10-30% of adults, and somnolence persists despite adequate sleep duration due to the disrupted quality. Narcolepsy is characterized by the brain's inability to regulate sleep-wake transitions, often due to loss of -producing neurons in the , leading to sudden sleep attacks where individuals fall asleep abruptly during wakeful activities. These episodes, lasting seconds to minutes, occur multiple times daily and are accompanied by chronic , reflecting 's role in stabilizing . The disorder typically onset in young adulthood, with deficiency confirmed in analyses. Idiopathic hypersomnia presents as prolonged, unrefreshing sleep exceeding 10-11 hours nightly, coupled with severe daytime sleepiness that naps do not alleviate, distinguishing it from other s. Unlike , it lacks or sleep attacks, but affected individuals often experience —profound grogginess upon waking—that compounds alertness impairments. The remains unclear, though hypersensitivity to sleep-promoting signals is hypothesized. The core mechanism linking these disorders to somnolence is circadian desynchronization, which accumulates by reducing sleep efficiency and depth when rest occurs out of phase with the internal clock. This misalignment suppresses wake-promoting signals from the , the master circadian pacemaker, while elevating homeostatic sleep pressure, culminating in impaired vigilance and cognitive performance. In primary disorders like OSA and , fragmented or loss further exacerbates this by preventing consolidated restorative , perpetuating a of and reduced alertness.

Medical Conditions

Somnolence frequently manifests as a secondary symptom in various infectious diseases, where it forms part of the adaptive "" syndrome. This behavioral response, triggered by proinflammatory cytokines such as interleukin-1 (IL-1) and (TNF), promotes and reduced activity to conserve energy during periods of fever and inflammation. These cytokines act on the to induce non-specific symptoms of , including profound and sleepiness, which help redirect metabolic resources toward immune defense rather than physical exertion. In conditions like viral or bacterial s, this cytokine-mediated can persist beyond the acute phase if inflammation remains unresolved, contributing to prolonged daytime somnolence. Endocrine and metabolic disorders also commonly underlie somnolence through disruptions in energy regulation and oxygen delivery. In , insufficient thyroid hormone production leads to a reduced metabolic rate, which slows overall physiological processes and impairs , resulting in excessive tiredness and somnolence. exacerbates this by decreasing levels, thereby limiting oxygen transport to the and causing that manifests as and drowsiness. Similarly, in , fluctuating blood glucose levels—whether hyperglycemic or hypoglycemic—disrupt cellular energy supply, leading to persistent and somnolence independent of overall glycemic control. Electrolyte disturbances, such as (low blood sodium), can induce somnolence by causing and disrupting neuronal function, particularly in severe cases. Neurological conditions often produce somnolence via direct impairment of arousal pathways. involves progressive loss in the , which compromises the brain's ability to maintain and results in . In , demyelination of axons disrupts neural signal transmission, contributing to primary characterized by increased somnolence and exhaustion that worsens with activity or heat. Post-stroke somnolence, or , arises from brain injury affecting regulatory centers, leading to prolonged daytime napping and reduced arousal that can persist for months. Beyond these categories, chronic pain syndromes and further contribute to somnolence through sustained physiological stress. , such as in or musculoskeletal disorders, creates a bidirectional with disruption, where pain-induced hyperarousal at night leads to daytime drowsiness and . In , reduced and associated sleep-disordered breathing cause intermittent , depriving the of oxygen and promoting as a compensatory response. These mechanisms highlight somnolence as an indicator of underlying systemic illness, often requiring targeted treatment of the primary condition to alleviate the symptom.

Medications and Substances

Numerous medications and substances can induce somnolence through their interactions with systems that regulate and sleep-wake cycles. medications, such as first-generation antihistamines exemplified by diphenhydramine, primarily cause drowsiness by antagonizing H1 receptors in the brain, thereby suppressing histaminergic arousal pathways. Benzodiazepines, like , promote somnolence via enhancement of gamma-aminobutyric acid () activity at GABAA receptors, increasing inhibitory neurotransmission in the and dampening excitatory signals. Similarly, opioids such as induce sedation through agonism of mu-opioid receptors, which inhibits ascending pathways originating from the . Other pharmaceuticals contribute to somnolence via diverse mechanisms often involving . antidepressants, including amitriptyline, frequently lead to drowsiness due to their potent blockade of H1 receptors and effects, which reduce . Antipsychotics, such as , can cause somnolence primarily through dopamine D2 receptor blockade in mesolimbic and nigrostriatal pathways, disrupting dopaminergic modulation of , although antagonism also plays a role in many agents. Chemotherapy agents, like , induce profound fatigue and somnolence in cancer patients through multifactorial pathways, including inflammatory cytokine release (e.g., interleukin-6) and direct affecting hypothalamic function. Recreational substances similarly impair alertness via targeted neuropharmacological actions. induces initial somnolence by potentiating inhibition and antagonizing excitation at NMDA receptors, leading to overall . , through its primary psychoactive component delta-9-tetrahydrocannabinol (THC), alters sleep architecture by activating CB1 cannabinoid receptors, which suppresses REM sleep and promotes subjective drowsiness, particularly in chronic users. Caffeine withdrawal, conversely, triggers somnolence via rebound accumulation of , which binds A1 and A2A receptors to enhance inhibitory sleep-promoting signals after chronic antagonism by the stimulant. Certain environmental exposures mimic sedative effects by compromising cerebral oxygenation and neural function. High-altitude , occurring above approximately 2,500 meters, induces daytime somnolence through chronic that disrupts quality, increases arousals, and impairs prefrontal cortical activity essential for sustained attention. exposure causes somnolence by binding with higher affinity than oxygen, resulting in hypoxic that reduces cerebral oxygen delivery and manifests as drowsiness in about 6% of symptomatic cases.

Clinical Presentation

Symptoms

Somnolence manifests primarily as an irresistible urge to sleep and a profound difficulty in maintaining , even during activities requiring . Affected individuals often report a strong desire to fall asleep at inappropriate times, accompanied by cognitive impairments such as reduced and inability to concentrate. A hallmark feature is the occurrence of , which are involuntary, brief lapses into lasting from a few seconds to about 30 seconds, during which the person may appear awake but is unresponsive. Observable sensory and behavioral effects include slowed reaction times, , and episodes of head nodding, where the head may droop forward momentarily as sleep encroaches. These signs reflect the brain's struggle to sustain , often leading to lapses in on tasks demanding vigilance. In particular, head nodding serves as a visible indicator of encroaching drowsiness, frequently observed during periods of inactivity. The intensity of these symptoms typically escalates in low-stimulation or monotonous environments, such as prolonged reading, watching lectures, or long-distance , where external cues to stay alert are minimal. Such situational triggers can precipitate sudden waves of sleepiness, heightening the risk of unintended dozing. Somnolence can present acutely with sudden onset, as seen in cases following acute events like infections or medication effects, resulting in immediate and intense drowsiness. In contrast, chronic somnolence involves persistent, ongoing symptoms that interfere with daily functioning over extended periods, often linked to underlying disorders like .

Associated Features

Somnolence is frequently accompanied by cognitive impairments, including reduced , memory lapses, and impaired , primarily attributable to underactivation in the . Studies on , a common inducer of somnolence, demonstrate that even partial sleep loss leads to significant declines in vigilance and , with (fMRI) revealing decreased activity during tasks requiring sustained attention and executive function. These deficits manifest as difficulty maintaining focus on complex tasks and errors in recall, exacerbating the challenges of daily cognitive demands. Mood alterations represent another key associated feature of somnolence, encompassing , depression-like symptoms, and emotional blunting, often linked to disruptions in serotonin pathways that regulate both and affective processing. In conditions involving , such as sleep-disordered breathing, individuals commonly report heightened and depressed mood alongside somnolence, with serotonin dysregulation implicated in impaired emotional regulation and reduced hedonic responsiveness. Serotonin neurons in the promote ; their hypoactivity during somnolent states contributes to flattened and increased vulnerability to depressive symptoms. Physical signs of somnolence include , clumsiness exemplified by slowed , and frequent yawning as a compensatory mechanism to alleviate drowsiness. arises from generalized reductions in , leading to diminished physical vigor and , while studies show that somnolence impairs control through slower reaction times and altered sensorimotor integration. Yawning, often observed in sleepy states, serves to increase cerebral blood flow and oxygenation, acting as a physiological response to counteract declining . In chronic somnolence, there is notable overlap with comorbid presentations such as and , where persistent excessive sleepiness blurs into motivational deficits resembling those in mood disorders. Research on in affective conditions highlights how prolonged somnolence correlates with reduced initiative and pleasure-seeking, with shared neurobiological underpinnings including prefrontal hypoactivity and imbalances. This comorbidity can intensify in disorders like , where somnolence exacerbates anhedonic states without resolving underlying sleep architecture issues.

Diagnosis and Assessment

Clinical Evaluation

The clinical evaluation of somnolence begins with a detailed history to assess the nature, onset, and context of (EDS). Clinicians inquire about duration and quality, including average nightly time, interruptions, and perceived refreshment upon waking, as insufficient (less than 7 hours per night for adults) is a common contributor to somnolence. Questions also explore daytime incidents, such as near-misses or accidents while driving, falling asleep during sedentary activities like reading or watching television, or episodes, which help quantify the severity and risks associated with EDS. Lifestyle factors are probed, including , irregular sleep schedules, or intake, and occupational demands that may disrupt circadian rhythms or lead to chronic . A comprehensive follows to identify potential underlying contributors. Evaluation includes measurement of (BMI) and neck circumference to assess obesity-related risks for , a frequent cause of somnolence, with neck circumferences greater than 17 inches in men or 16 inches in women indicating higher suspicion. The thyroid gland is palpated for enlargement suggestive of , which can manifest as and sleepiness. checks for deficits such as tremors, , or altered mental status that might point to disorders. General assessment covers signs of chronic illness, such as or , to guide further investigation. Screening questionnaires provide a standardized subjective measure of sleepiness during the initial evaluation. The Stanford Sleepiness Scale, a seven-point self-rating tool, allows patients to rate their current level of on a scale from 1 (alert) to 7 (almost asleep), offering an immediate snapshot useful for bedside assessment. The (ESS), an eight-item questionnaire scoring the likelihood of dozing in common situations (0-3 per item, total 0-24), is also employed; scores above 10 indicate abnormal sleepiness, aiding in initial . Differential diagnosis is pursued through targeted historical inquiries to distinguish somnolence from mimics. For , clinicians ask about persistent low mood, , or , as these can overlap with EDS but require distinct management. To rule out , questions focus on symptoms like cold intolerance, weight gain, or constipation, prompting consideration of function if indicated. This structured approach ensures somnolence is contextualized within broader clinical features, such as those reported in the patient's symptoms.

Objective Tests

Objective tests for somnolence provide quantifiable measures of sleep propensity and underlying sleep disturbances, complementing clinical history by offering objective data on daytime sleepiness and nocturnal sleep quality. These tests are typically conducted in controlled laboratory settings or using ambulatory devices, following standardized protocols established by organizations. The (MSLT) is a key objective assessment of daytime sleepiness, involving a series of scheduled naps following an overnight . The patient is given four to five opportunities to nap, spaced two hours apart, in a quiet, dimly lit , with each nap terminated after sleep onset or 20 minutes if no sleep occurs. Sleep latency for each nap is measured as the time from lights out to the first epoch of sleep, and the mean sleep latency across naps is calculated; a value of less than 8 minutes indicates pathological sleepiness, while the presence of two or more sleep-onset REM periods supports a diagnosis of . This test quantifies the tendency to fall asleep involuntarily and helps differentiate central hypersomnias from other causes of somnolence. The Maintenance of Wakefulness Test (MWT) evaluates an individual's ability to resist under soporific conditions, serving as a measure of rather than sleep propensity. Performed similarly to the MSLT with four 40-minute trials spaced two hours apart in a monotonous environment, the patient is instructed to stay awake while seated comfortably; is recorded as the time to the first of or 40 minutes if is maintained. A mean of 8 minutes or less across trials signifies severe impairment in maintaining , often used to assess or fitness for safety-sensitive occupations. Unlike the MSLT, the MWT focuses on sustained and does not diagnose specific disorders but highlights excessive somnolence's functional impact. Actigraphy offers a non-invasive, long-term of sleep-wake patterns and s using a wrist-worn that detects movement and, in some devices, light exposure. Worn continuously for one to two weeks, the device generates activity logs analyzed by algorithms to estimate parameters such as total time, efficiency, and napping frequency, which can reveal fragmented rest-activity cycles contributing to somnolence. It is particularly useful for assessing circadian misalignment in disorders like delayed sleep phase syndrome, where irregular patterns correlate with persistent sleepiness, and provides over extended periods compared to single-night lab tests. The recommends for evaluating and circadian rhythm sleep-wake disorders in both adults and children. Polysomnography (PSG) is an overnight laboratory study that records multiple physiological signals to identify sleep disruptions causing secondary somnolence, such as respiratory events or arousals. Electroencephalography (EEG), electrooculography (EOG), and electromyography (EMG) monitor brain activity, eye movements, and muscle tone, respectively, alongside measures of airflow, respiratory effort, and oxygen saturation to detect conditions like that fragment . Abnormal findings, including frequent arousals or reduced sleep efficiency, explain daytime somnolence by quantifying nocturnal quality; PSG is often prerequisite to daytime tests like the MSLT for ruling out confounds. As the gold standard for diagnosing sleep-related breathing disorders, it provides comprehensive data on architecture essential for targeted management.

Severity and Impact

Classification

Somnolence, or , is classified using standardized subjective scales that quantify its severity based on self-reported likelihood of dozing or perceived alertness. The (ESS) is a widely used 8-item that assesses the probability of dozing in common situations, with each item scored from 0 (would never doze) to 3 (high chance of dozing), yielding a total score ranging from 0 to 24. A score greater than 10 indicates , with mild severity corresponding to 11-12 (slight increase over normal), moderate to 13-15 (notable interference in daily activities), and severe to greater than 16 (high risk of unintended sleep episodes). Other subjective tools include the (KSS), a 9-point rating of immediate subjective sleepiness, where 1 denotes "extremely alert" and 9 indicates "very sleepy, great effort to stay awake, or fighting sleep." The (VAS) for drowsiness provides a continuous measure, typically a 100-mm line where respondents mark their current level of sleepiness from 0 (fully alert) to 100 (extremely drowsy), offering a simple, real-time assessment often used in clinical or research settings. In , somnolence severity is graded qualitatively as mild (occasional lapses in with minimal in daily functioning), moderate (frequent drowsiness that is manageable but disrupts routine tasks), or severe (uncontrollable sleepiness posing risks, such as impaired or work ). Recent refinements to the in the have focused on cultural adaptations to enhance validity across diverse populations, including validated Malay and versions that adjust items for local contexts while maintaining reliability.

Functional Consequences

Somnolence profoundly disrupts daily life, manifesting as reduced productivity in professional and academic environments. Individuals affected by often struggle with maintaining focus and completing tasks efficiently, with surveys indicating that up to 47% report direct negative effects on work or . This impairment extends to social domains, where sleepiness fosters withdrawal from interactions and heightens , straining personal relationships and contributing to feelings of . For instance, , a key driver of somnolence, has been linked to neurobehavioral changes that promote social separation and , exacerbating interpersonal tensions. Safety implications of somnolence are particularly acute, elevating risks across multiple settings. In transportation, —closely tied to somnolence—increases the likelihood of crashes by approximately 30% for those sleeping 6-7 hours nightly compared to those achieving 8 or more hours, with recent estimates suggesting involvement in approximately police-reported crashes annually, resulting in thousands of injuries and around 700 fatalities (as of 2022 data). errors also rise due to diminished , increasing the potential for accidents in safety-critical roles. Among older adults, correlates with heightened fall risks, compounding vulnerability in this demographic. Over the long term, untreated somnolence contributes to adverse health trajectories, including progression of and cognitive decline. Excessive daytime sleepiness is associated with elevated risks of cardiovascular events such as heart disease and , independent of underlying conditions like . Similarly, it heightens the odds of by 26% and by 68%, underscoring its role in accelerating brain aging. Recent 2025 estimates indicate that up to 33% of adults experience daily, with rates climbing to 10-38% among shift workers due to circadian misalignment.

Management and Treatment

Non-Pharmacological Approaches

Non-pharmacological approaches to managing somnolence emphasize behavioral, , and environmental modifications to improve quality and reduce daytime sleepiness. These strategies target underlying disruptions in sleep patterns and circadian rhythms without relying on medications, often serving as first-line interventions recommended by clinical guidelines. Sleep hygiene practices form the foundation of these approaches, involving consistent routines to promote restorative . Individuals are advised to maintain a fixed -wake , aiming for 7 to of per night to align with natural circadian needs and minimize accumulation. Avoiding screens and exposure at least one hour before bedtime helps preserve production, while creating an optimal —cool (around 18-22°C), dark, and quiet—enhances onset and . Behavioral interventions, such as adaptations of (CBT-I), address maladaptive thoughts and habits contributing to somnolence. CBT-I components like —using the bed only for sleep and sex—and sleep restriction, which limits time in bed to build sleep drive, have demonstrated efficacy in reducing daytime sleepiness by improving overall sleep efficiency. , involving exposure to bright light (e.g., 10,000 for 30 minutes in the morning), aids circadian realignment, particularly for those with disrupted rhythms, and when combined with CBT-I, it further alleviates insomnia-related sleepiness. Lifestyle modifications play a key role in sustaining throughout the day. Engaging in regular , such as 30 minutes of moderate activity daily (e.g., walking or ), boosts quality and reduces somnolence by enhancing circadian regulation and energy levels. Strategic napping, limited to short 20-minute power naps early in the afternoon, can restore vigilance without interfering with nighttime , as longer naps may exacerbate grogginess. Dietary adjustments, including avoiding heavy or spicy meals close to , prevent digestive discomfort that disrupts continuity and contributes to daytime . For individuals affected by occupational factors like , targeted adjustments mitigate somnolence risks. Optimizing shift schedules through forward-rotating patterns (e.g., shifts) and allowing recovery days reduces cumulative disruption and associated drowsiness. Workplace accommodations, such as scheduled breaks for rest or access to quiet nap areas during shifts, support alertness and safety, particularly in high-risk environments.

Pharmacological Interventions

Pharmacological interventions for somnolence primarily involve wake-promoting agents that target systems to enhance alertness and reduce excessive daytime sleepiness, particularly in conditions such as and (OSA). These medications are typically considered after addressing underlying causes and non-pharmacological options, with selection based on efficacy, side effect profile, and patient-specific factors. Stimulants like and are first-line options for promoting . acts as a weak inhibitor of the , increasing extracellular levels without significantly affecting release, which contributes to its wake-promoting effects. It is approved by the U.S. (FDA) for excessive daytime sleepiness associated with , OSA, and shift work disorder, with a typical dosing regimen of 200 mg once daily in the morning. The (AASM) provides a strong recommendation for in adults with and based on evidence from randomized controlled trials showing improved maintenance of . , the longer-acting R-enantiomer of , shares a similar and indications, offering sustained with once-daily dosing of 150-250 mg. Clinical studies demonstrate its efficacy in reducing sleepiness in OSA and patients, with comparable tolerability to . Amphetamines, such as , serve as second-line agents due to their potential for abuse and more pronounced sympathomimetic effects. blocks the of and norepinephrine by inhibiting their transporters, thereby enhancing synaptic concentrations of these catecholamines to improve . It is FDA-approved for at doses of 10-60 mg/day, divided as needed, but is used cautiously in somnolence management owing to risks of dependence and cardiovascular stimulation. The AASM conditionally recommends for adults with central disorders of hypersomnolence when first-line agents are ineffective or contraindicated. Other agents include and , which offer alternative mechanisms for patients intolerant to traditional stimulants. functions as a and , elevating levels of these neurotransmitters to promote without amphetamine-like . FDA-approved for in and OSA at doses of 75-150 mg once daily, it has demonstrated significant improvements in on objective tests like the Maintenance of Wakefulness Test in clinical trials. The AASM strongly recommends for adults with . , a selective , enhances by blocking autoreceptors, leading to increased release in wake-promoting regions. It is FDA-approved for at 17.8-35.6 mg once daily and shows efficacy in reducing sleepiness, with the AASM providing a strong recommendation for its use in adults. Treatment considerations include monitoring for common side effects such as , , anxiety, and increased or , which are more frequent with stimulants like , , and . Cardiovascular strain necessitates caution in patients with heart disease, and all agents carry risks of interactions, particularly with CYP450 modulators. The AASM 2021 guidelines emphasize individualized therapy, starting with lower doses and titrating based on response, while advising against long-term use without reassessment. For residual sleepiness in OSA despite therapy, is recommended by AASM guidelines, and both and are FDA-approved. In December 2024, the FDA approved (Zepbound) for moderate-to-severe OSA in adults with to reduce apnea events, potentially alleviating associated somnolence by treating the underlying condition.

References

  1. [1]
    Somnolence (Drowsiness): What It Is, Causes & Treatment
    Somnolence, or drowsiness, is when you want to fall asleep. It can be a symptom of an underlying condition or a medication side effect.
  2. [2]
    Drowsiness: MedlinePlus Medical Encyclopedia
    Jul 8, 2023 · Drowsiness refers to feeling more sleepy than normal during the day. People who are drowsy may fall asleep when they do not want to or at times which can lead ...
  3. [3]
    Excessive Daytime Sleepiness - AAFP
    Mar 1, 2009 · The most common causes of excessive daytime sleepiness are sleep deprivation, obstructive sleep apnea, and sedating medications.
  4. [4]
  5. [5]
    Somnolence: What Is It, Causes, Treatment, and More - Osmosis
    Somnolence is defined as a state of drowsiness or strong desire to fall asleep and is commonly associated with an underlying condition.
  6. [6]
    Medical Definition of Somnolence - RxList
    Somnolence: Sleepiness, the state of feeling drowsy, ready to fall asleep. A person experiencing somnolence is somnolent and is acting somnolently.
  7. [7]
    SOMNOLENCE Definition & Meaning - Merriam-Webster
    The meaning of SOMNOLENCE is the quality or state of being drowsy : sleepiness.
  8. [8]
    The Development of Sleep Medicine: A Historical Sketch - PMC
    In the 19th and early 20th century, the medical community became aware of three distinct illnesses which all had pathological sleepiness as a prominent symptom.
  9. [9]
    Distinguishing sleepiness and fatigue: focus on definition ... - PubMed
    Sleepiness is multidimensional and has many causes (multidetermined) and distinguished from fatigue by a presumed impairment of the normal arousal mechanism.
  10. [10]
    Hypersomnia: What It Is, Causes, Symptoms & Treatment
    Hypersomnia is any condition that makes you feel extremely sleepy during the day. This happens even though you get a healthy amount of sleep (or more than ...Hypersomnia Disorders · Idiopathic hypersomnia · Kleine-Levin Syndrome
  11. [11]
    Approach to the patient with excessive daytime sleepiness - UpToDate
    Sep 2, 2025 · In the ICSD-3-TR, hypersomnolence is used to describe symptoms including excessive sleepiness and increased sleep duration, and hypersomnia ...
  12. [12]
    Neuroanatomy, Nucleus Suprachiasmatic - StatPearls - NCBI - NIH
    The suprachiasmatic nucleus (SCN) is a bilateral structure located in the anterior part of the hypothalamus. It is the central pacemaker of the circadian timing ...
  13. [13]
    Physiology, Circadian Rhythm - StatPearls - NCBI Bookshelf
    Circadian rhythm is the 24-hour internal clock in our brain that regulates cycles of alertness and sleepiness by responding to light changes in our environment.
  14. [14]
    Sleep and Circadian Regulation of Cortisol: A Short Review - PMC
    The central circadian pacemaker (CCP) located in the suprachiasmatic nucleus (SCN) of the hypothalamus drives the 24-hour pattern in cortisol, which functions ...
  15. [15]
    Adenosine, caffeine, and sleep–wake regulation - PubMed Central
    Huston and co‐workers suggested that “adenosine's sleep promoting effects result from its signaling to cease behavioral activity in order to prevent excessive ...
  16. [16]
    Adenosine in sleep and wakefulness - PubMed
    Our hypothesis is that adenosine accumulates in the extracellular space of the basal forebrain during wakefulness, increasing the sleep propensity.
  17. [17]
    Orexin/Hypocretin and Organizing Principles for a Diversity of Wake ...
    It seems that without the orexin/hypocretin system, wakefulness is prone to instability in the face of rapid perturbations in the environment, and processes ...
  18. [18]
    Physiology, Sleep Patterns - StatPearls - NCBI Bookshelf
    A two-process model developed by Borbely in 1982 demonstrates how sleep-wake is regulated.[16] This model describes that there are two main processes ...Missing: somnolence | Show results with:somnolence
  19. [19]
    Effect of Lesions of the Ventrolateral Preoptic Nucleus on NREM and ...
    Neurons in the ventrolateral preoptic nucleus (VLPO) in rats show c-fos activation after sleep and provide GABAergic innervation of the major monoamine arousal ...
  20. [20]
    [PDF] Circadian Rhythm Sleep-Wake Disorders
    A chronic or recurrent pattern of sleep-wake rhythm disruption, primarily due to alteration of the endogenous circadian timing system or its entrainment ...
  21. [21]
    Shift Work and Shift Work Sleep Disorder - PubMed Central - NIH
    A subset of shift workers develops shift work disorder (SWD), a condition that is triggered by circadian misalignment and which results in insomnia and/or ...Missing: somnolence | Show results with:somnolence
  22. [22]
    Excessive sleepiness in shift work disorder: a narrative review of the ...
    Shift work sleep disorder (SWSD), also known as shift work disorder (SWD), is a circadian rhythm sleep disorder characterized by insomnia and/or excessive ...
  23. [23]
    Shift Work and Sleep: Medical Implications and Management - PMC
    Due to fatigue and somnolence, shift workers cannot perform their duties efficiently and the productivity outcome of work is also affected [90].
  24. [24]
    Delayed sleep phase - Symptoms and causes - Mayo Clinic
    Sep 21, 2023 · People with this sleep disorder have sleep patterns that are delayed two hours or more from usual sleep patterns. They go to sleep later and ...
  25. [25]
    Delayed Sleep Phase Disorder - Sleep Foundation
    Feb 14, 2024 · Excessive Sleepiness: You may struggle to stay awake during the day or even find yourself nodding off. Difficulty Concentrating: Without ...What Is Delayed Sleep Phase... · Symptoms
  26. [26]
    Advanced Sleep Phase Syndrome | Stanford Health Care
    Advanced sleep phase syndrome is a disorder in which the timing of sleep and the peak period of alertness are advanced several hours relative to societal clock.
  27. [27]
    Advanced Sleep Phase Disorder
    Feb 14, 2024 · Advanced sleep phase disorder is characterized by early evening sleepiness and early morning waking. · An earlier sleep-wake cycle can interfere ...What Is Advanced Sleep... · Symptoms
  28. [28]
    Advanced Sleep Phase Disorder (ASPD) - Sleep Health Foundation
    Apart from being inconvenient, ASPD can cause insomnia in the early morning, insufficient sleep, daytime sleepiness and fatigue. It can also increase the ...
  29. [29]
    Non-24-Hour Sleep-Wake Disorder - Circadian Rhythm Disorder
    Non-24-hour sleep-wake disorder (N24) is a circadian rhythm sleep disorder in which an individual's biological clock fails to synchronize to a 24-hour day.
  30. [30]
    Non-24-hour sleep-wake rhythm disorder - UpToDate
    Individuals with non-24-hour sleep-wake rhythm disorder (N24SWD) are unable to maintain appropriate alignment with the 24-hour environment, so each day their ...Missing: hypersomnia | Show results with:hypersomnia
  31. [31]
    Non-24-hour sleep-wake syndrome - Orphanet
    The diagnosis is based on recurrent or relapsing insomnia and daytime drowsiness. The disorder should be suspected in blind individuals with recurrent insomnia ...
  32. [32]
    Obstructive Sleep Apnea - StatPearls - NCBI Bookshelf
    Mar 4, 2025 · This disruption leads to fragmented, nonrestorative sleep. Symptoms include loud, disruptive snoring, witnessed apneas, and excessive daytime ...Missing: somnolence | Show results with:somnolence
  33. [33]
    Excessive Daytime Sleepiness in Obstructive Sleep Apnea ...
    Many patients with obstructive sleep apnea (OSA) experience excessive daytime sleepiness (EDS), which can negatively affect daily functioning, cognition, mood, ...
  34. [34]
    Narcolepsy | National Institute of Neurological Disorders and Stroke
    Jan 10, 2025 · Sleepiness in narcolepsy is often like a “sleep attack,” where an overwhelming feeling of sleepiness comes on quickly.What is narcolepsy? · Who is more likely to get... · What are the latest updates on...
  35. [35]
    The Science of Narcolepsy - Division of Sleep Medicine
    Research has revealed that narcolepsy with cataplexy is caused by a lack of orexins, also known as hypocretins, key brain chemicals that help sustain alertness.Science of Sleep: What is Sleep? · Healthy Sleep · How is Sleep Regulated?
  36. [36]
    Deficiency of orexin signaling during sleep is involved in abnormal ...
    Oct 5, 2023 · Narcolepsy is a sleep disorder caused by deficient orexin signaling due to orexin neuron degeneration. However, the neural mechanisms ...
  37. [37]
    Idiopathic Hypersomnia - StatPearls - NCBI Bookshelf - NIH
    ... Idiopathic hypersomnia is characterized by excessive daytime sleepiness, uncontrollable need to sleep with long unrefreshing naps, and difficulty waking up from ...
  38. [38]
    Idiopathic hypersomnia - Symptoms and causes - Mayo Clinic
    Oct 30, 2024 · Idiopathic hypersomnia is a condition that causes people to be very sleepy during the day even after a full night of sleep.<|control11|><|separator|>
  39. [39]
    Idiopathic Hypersomnia - Neurologic Disorders - Merck Manuals
    Idiopathic hypersomnia is excessive daytime sleepiness with or without a long sleep time; it is differentiated from narcolepsy by lack of cataplexy ...
  40. [40]
    Sleep Deprivation and Circadian Disruption - PubMed Central - NIH
    The specific mechanisms by which disrupted circadian clocks cause changes in brain, behavior, and peripheral physiology remain unknown. One hypothesis is that ...Missing: alertness | Show results with:alertness
  41. [41]
    Circadian Rhythm and Sleep Disruption: Causes, Metabolic ...
    The circadian process influences alertness, and the sleep process is hypnogenic, rising during wakefulness and falling during sleep in a manner akin to an ...Circadian Rhythm And Sleep... · Ii. The Circadian System · A. Sleep Restriction And...
  42. [42]
    The Legacy of Sickness Behaviors - PMC - PubMed Central - NIH
    Dec 3, 2020 · The first clue that cytokines are involved in human sickness behaviors came from phase 1 clinical trials for cancer. Systemic injections of ...
  43. [43]
    Cytokine-induced sickness behavior - ScienceDirect.com
    Proinflammatory cytokines act in the brain to induce non-specific symptoms of infection, including fever and profound psychological and behavioral changes.Missing: somnolence | Show results with:somnolence
  44. [44]
    Sickness behavior, its mechanisms and significance
    Apr 21, 2008 · The major cytokines, interleukin-1, tumor necrosis factor alpha, and others, all act on the hypothalamus to provoke alterations in the normal ...<|separator|>
  45. [45]
    Sickness Behavior - an overview | ScienceDirect Topics
    These behavioral changes are provoked by proinflammatory cytokines (PICs) such as interleukin 1 (IL-1), tumor necrosis factor alpha (TNF-α), and IL-6, which ...
  46. [46]
    Hypothyroidism (underactive thyroid) - Symptoms and causes
    Dec 10, 2022 · But as your metabolism continues to slow, you may develop more-obvious problems. Hypothyroidism symptoms may include: Tiredness. More ...Missing: somnolence | Show results with:somnolence
  47. [47]
    12 signs and symptoms of hypothyroidism (underactive thyroid)
    Hypothyroidism may manifest in the following ten signs: fatigue, excessive somnolence, increased cold sensitivity, pale and dry skin, face puffiness, hoarse ...Bradycardia (slow heart rate) · Turner syndrome · Hashimoto's thyroiditis
  48. [48]
    10 Symptoms of Anemia You Shouldn't Ignore | Texas Medical Institute
    Jul 24, 2020 · Low levels of hemoglobin prevent adequate oxygen from reaching the brain. Blood vessels swell, blood pressure drops, and it can result in ...
  49. [49]
    Anemia and Brain Fog: 5 Clarity-Boosting Strategies - InsideTracker
    Dec 6, 2023 · Low iron levels can result in reduced oxygen supply to the brain, which can lead to memory problems and concentration issues.
  50. [50]
    Fatigue in Patients with Diabetes: A Review - PMC - PubMed Central
    Fluctuations in blood glucose levels, regardless of overall blood glucose control as measured by hemoglobin A1c, may contribute to fatigue. There is ...
  51. [51]
    Diabetes Fatigue: Causes, Management, and More - Healthline
    Mar 27, 2025 · Fluctuations in blood sugar levels, whether high (hyperglycemia) or low (hypoglycemia), can lead to fatigue in those with diabetes.
  52. [52]
    Circadian and Sleep Disorders in Parkinson's Disease - PMC
    1988). Patients exposed to dopamine agonists, however, experience excessive daytime somnolence and sudden onset sleep. Although DA participates in both ...
  53. [53]
    Sleep and circadian rhythms in Parkinson's disease and preclinical ...
    Jan 9, 2022 · Abilities to maintain arousal are compromised under low dopamine conditions, as in Parkinson's disease [103,104,105]. Since this review concerns ...
  54. [54]
    Fatigue in multiple sclerosis: mechanisms and management - PubMed
    Fatigue may manifest as exhaustion, lack of energy, increased somnolence, or worsening of MS symptoms. Activity and heat typically serve to exacerbate symptoms ...
  55. [55]
    Causes of fatigue | MS Society
    When fatigue is thought to be a direct result of damage to the central nervous system, like demyelination or inflammation, we call it 'primary fatigue'. MS ...Causes Of Fatigue · Ms Fatigue And The Central... · Other Ms Symptoms<|separator|>
  56. [56]
    Excessive Daytime Sleepiness in Stroke Survivors - PubMed Central
    Excessive daytime sleepiness (EDS) is a prevalent symptom among stroke survivors. This symptom is an independent risk factor for stroke.
  57. [57]
    Hypersomnia in stroke ischemic - ScienceDirect.com
    Hypersomnia/excessive daytime sleepiness post-stroke is a condition of prolonged daytime napping and nighttime sleep following a cerebrovascular accident.Case Report · Case Presentation · Discussion
  58. [58]
    Sleep disorders in chronic pain and its neurochemical mechanisms
    Jun 1, 2023 · There is considerable evidence showing a reciprocal association between pain and sleep, especially in CP.
  59. [59]
    Sleepiness comorbid to musculoskeletal pain is associated with ...
    Musculoskeletal (MSK) pain and hypersomnolence (HPS) are very disabling conditions that may share some pathophysiological factors.
  60. [60]
    Sleep Disordered Breathing and Heart Failure: What Does ... - JACC
    Sep 6, 2017 · Sleep-disordered breathing (SDB) is common in patients with heart failure (HF), and it is associated with frequent episodic hypoxemia, ...Missing: somnolence | Show results with:somnolence
  61. [61]
    Sleep Disordered Breathing in Heart Failure - PubMed Central - NIH
    Sleep disordered breathing (SDB) is the most common comorbidity in heart failure (HF), occurring in 50–80% of patients. SDB accelerates the progression of HF ...Missing: somnolence | Show results with:somnolence
  62. [62]
    Mechanisms by which pharmacologic agents may contribute to fatigue
    One major mechanism by which medications can cause fatigue is by central nervous system (CNS) depression. CNS depression can result from decreased excitatory ...
  63. [63]
    Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms ...
    The rates of somnolence were positively correlated to dose and duration for some antipsychotics, but not for others. Many factors, including antipsychotic per ...Missing: tricyclic antidepressants
  64. [64]
    Sleep Disorders (PDQ®) - NCI - National Cancer Institute
    Jul 17, 2024 · Antipsychotics such as quetiapine have sedating effects caused mainly by the blockade of histamine receptors. However, these agents should be ...
  65. [65]
    Sleep abnormalities associated with alcohol, cannabis, cocaine, and ...
    This review summarizes this research and discusses the clinical implications of sleep abnormalities in the treatment of substance use disorders.
  66. [66]
    Polysomnographic sleep disturbances in nicotine, caffeine, alcohol ...
    Results: Our review indicates that these substances have significant impact on sleep and that their effects differ during intoxication, withdrawal, and chronic ...
  67. [67]
    The Physiology of High-Altitude Exposure - NCBI - NIH
    The decrease of ambient Po2 is the direct cause of many medical problems at altitudes above 2,438 m (8,000 ft). This decrease causes several interrelated ...Missing: monoxide | Show results with:monoxide
  68. [68]
    Carbon Monoxide Toxicity - StatPearls - NCBI Bookshelf
    ### Symptoms of Carbon Monoxide Poisoning (Including Somnolence)
  69. [69]
    Microsleep: Symptoms, Causes, and Safety Risks - Sleep Foundation
    Jul 10, 2025 · Microsleep is a phenomenon in which a person falls asleep for 15 seconds or less. Learn about the symptoms, risks, and treatments for ...Missing: irresistible blurred
  70. [70]
    Microsleep: Symptoms, Causes, Safety, and Prevention - Healthline
    Oct 17, 2018 · Microsleep refers to periods of sleep that last from a few to several seconds. People who experience these episodes may doze off without realizing it.Missing: blurred | Show results with:blurred
  71. [71]
    Recognition and Management of Excessive Sleepiness in the ...
    The principal causes of excessive sleepiness in primary disorders of sleep-wake include (1) fragmented sleep (eg, obstructive sleep apnea), (2) pathological ...
  72. [72]
    Excessive sleepiness: Causes, symptoms, and treatment
    Oct 26, 2019 · being unable to get to sleep · waking continually throughout the night · waking very early in the morning and being unable to fall back to sleep.Causes · Symptoms · Diagnosis
  73. [73]
    Sleep deprivation: Impact on cognitive performance - PubMed Central
    The decrease in attention and working memory due to SD is well established. Vigilance is especially impaired, but a decline is also observed in several other ...Missing: somnolence | Show results with:somnolence
  74. [74]
    The effects of sleep deprivation on cognitive flexibility: a scoping ...
    Jul 22, 2025 · During sleep deprivation, they experience reduced activation in the prefrontal cortex and hippocampus, leading to impaired cognitive flexibility ...Missing: somnolence | Show results with:somnolence
  75. [75]
    Neurocognitive Consequences of Sleep Deprivation - PMC
    Deficits in cognitive performance requiring working memory result in difficulty determining the scope of a problem due to changing or distracting information, ...
  76. [76]
    An exploratory study on the association between serotonin and ...
    Jul 21, 2023 · Patients with SDB can experience daytime symptoms such as sleepiness and excessive somnolence, depressed mood, irritability, and cognitive ...
  77. [77]
    Sleep and Rhythm Consequences of a Genetically Induced Loss of ...
    Serotonin helps maintain wakefulness, but also conditions later sleep episodes, as blockade of serotonin synthesis causes long–lasting, complete insomnia in ...Missing: somnolence | Show results with:somnolence
  78. [78]
    Serotonin control of sleep-wake behavior - PubMed
    It is currently accepted that serotonin (5-HT) functions predominantly to promote wakefulness (W) and to inhibit REM (rapid eye movement) sleep (REMS).Missing: disrupted | Show results with:disrupted
  79. [79]
    Sleep deprivation affects gait control - PMC - PubMed Central
    Oct 26, 2021 · Our results suggest that partial or total sleep deprivation leads to a decrease in the performance in the sensorimotor control of gait.Missing: somnolence | Show results with:somnolence
  80. [80]
    Functional and Economic Impact of Sleep Loss and ... - NCBI - NIH
    Sleepy drivers tend to display reduced vigilance, slow reaction times, and loss of steering control. Steering impairment in OSA, sleep deprivation, and alcohol ...Missing: somnolence | Show results with:somnolence
  81. [81]
    The thermoregulatory theory of yawning: what we know from over 5 ...
    Yawning is often interpreted as an indication of boredom, lack of interest, and sleepiness, and some have even hypothesized that yawning is simply an expression ...Missing: somnolence | Show results with:somnolence
  82. [82]
    Hypersomnia in Mood Disorders: a Rapidly Changing Landscape
    Apr 17, 2015 · Hypersomnia, defined as excessive daytime sleepiness (EDS) and/or total sleep time, commonly occurs in patients with mood disorders and is ...Missing: irritability | Show results with:irritability
  83. [83]
    Disentangling fatigue from anhedonia: a scoping review - PMC
    Aug 7, 2020 · Fatigue and anhedonia are commonly reported, co-occurring clinical symptoms associated with chronic illnesses.Missing: somnolence | Show results with:somnolence
  84. [84]
    The Assessment, Diagnosis, and Treatment of Excessive Sleepiness
    Careful monitoring and follow-up of patients with excessive daytime sleepiness, including counseling and long-term support, are essential to ensure treatment ...
  85. [85]
    Recommended protocols for the Multiple Sleep Latency Test and ...
    A minimum of 4 naps is required for the MSLT because the ICSD-3 diagnostic criteria are based on a minimum of 4 naps, and fewer naps diminish the reliability of ...ABSTRACT · BACKGROUND · PROTOCOLS FOR MSLT · PROTOCOLS FOR MWT
  86. [86]
    [PDF] Practice Parameters for Clinical Use of the Multiple Sleep Latency ...
    The test is based on the premise that the degree of sleepiness is reflected by sleep latency [2.2]. The MSLT is con- sidered the de facto standard for ...
  87. [87]
    Use of Actigraphy for the Evaluation of Sleep Disorders and ...
    This clinical practice guideline is intended to update the previously published American Academy of Sleep Medicine (AASM) practice parameters on the use of ...Skip main navigation · ABSTRACT · INTRODUCTION · CLINICAL PR ACTICE...
  88. [88]
    Polysomnography - PubMed
    PSG is considered to be the gold standard for diagnosing sleep-related breathing disorders, which include obstructive sleep apnea (OSA), central sleep apnea, ...Missing: somnolence | Show results with:somnolence
  89. [89]
    Sleep Study - StatPearls - NCBI Bookshelf - NIH
    Aug 14, 2023 · Polysomnogram (PSG) should be performed during the patient's habitual sleep period. Patients present to the sleep center in the evening and are ...Missing: somnolence | Show results with:somnolence
  90. [90]
    About the ESS - Epworth Sleepiness Scale
    The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life ...
  91. [91]
    Epworth Sleepiness Scale | Asthma + Lung UK
    What does my score mean? · 0-5 lower normal daytime sleepiness · 6-10 normal daytime sleepiness · 11-12 mild daytime symptoms · 13-15 moderate daytime symptoms · 16- ...
  92. [92]
    Karolinska Sleepiness Scale (KSS) | SKYbrary Aviation Safety
    Scoring · 1 = extremely alert · 2 = very alert · 3 = alert · 4 = rather alert · 5 = neither alert nor sleepy · 6 = some signs of sleepiness · 7 = sleepy, but no effort ...
  93. [93]
    A visual analog scale for the assessment of mild sleepiness in ... - NIH
    This study aimed to investigate the efficacy of a Visual Analog Scale (VAS) to assess sleepiness, compared to ESS.
  94. [94]
    [PDF] table-for-grading-severity-of-adult-pediatric-adverse-events.pdf
    Note: In the classification of adverse events, the term “severe” is not the same as “serious.” Severity is an indication of the intensity of a specific event ( ...
  95. [95]
    Validation of the Malay version of Epworth sleepiness scale for ...
    Dec 19, 2023 · ESS-CHAD has been translated and cross-culturally adapted into Malay version for the Malaysian population, and found to be valid and reliable.Missing: 2020s | Show results with:2020s
  96. [96]
    Validity and reliability of the Spanish version of the Epworth ... - NIH
    May 17, 2025 · Total scores range from 0 to 24, with higher scores indicating a higher risk of sleepiness [1, 25]. The present study used a Spanish version ...
  97. [97]
    Daytime sleepiness takes a toll on Americans, impacting daily life
    Oct 1, 2024 · According to the survey, 47% of respondents report that sleepiness negatively impacts their productivity, making it challenging to stay focused ...Missing: consequences somnolence
  98. [98]
    Sleep loss causes social withdrawal and loneliness - PubMed Central
    Aug 14, 2018 · This study shows that sleep loss leads to a neurobehavioral phenotype of human social separation and loneliness, one that is transmittable to non-sleep- ...Missing: somnolence irritability
  99. [99]
  100. [100]
    Drowsy Driving: Avoid Falling Asleep Behind the Wheel | NHTSA
    NHTSA estimates that in 2017, 91,000 police-reported crashes involved drowsy drivers. These crashes led to an estimated 50,000 people injured and nearly 800 ...
  101. [101]
    Fatigue and its management in the workplace - ScienceDirect.com
    Excessive sleepiness in the workplace and on highways is a serious safety hazard, and insufficient or disrupted sleep results in numerous accidents and adverse ...
  102. [102]
    Excessive daytime sleepiness and falls among older men and women
    Jul 5, 2015 · Excessive daytime sleepiness (EDS) has been associated with an increased risk for falls among clinical samples of older adults.
  103. [103]
    Causal Association Between Subtypes of Excessive Daytime ...
    Dec 12, 2023 · Among patients with OSA, EDS has been shown to associate with inflammation, cognitive decline, and adverse cardiovascular events compared with ...
  104. [104]
    Effect of Excessive Daytime Sleepiness and Long Sleep Duration on ...
    Our meta-analysis found that EDS was associated with increased risk of both cognitive decline and dementia (26% and 68%, respectively). Therefore, EDS may ...Missing: somnolence | Show results with:somnolence
  105. [105]
    Shift work sleep disorder: prevalence and consequences beyond ...
    Conclusion: These findings suggest that individuals with shift work sleep disorder are at risk for significant behavioral and health-related morbidity ...
  106. [106]
    Excessive Daytime Sleepiness Medicine: Causes & Treatments
    May 16, 2025 · Medications help manage and reduce symptoms of EDS, but they are not a cure, and ongoing treatment may be necessary to control the condition.Missing: definition | Show results with:definition
  107. [107]
    New guideline provides clinical recommendations for treating sleep ...
    Mar 31, 2025 · “The AASM guideline will help clinicians determine the best treatment options for their patients to improve excessive daytime sleepiness, ...
  108. [108]
    Sleep tips: 6 steps to better sleep - Mayo Clinic
    1. Stick to a sleep schedule · 2. Pay attention to what you eat and drink · 3. Create a restful environment · 4. Limit daytime naps · 5. Include physical activity ...<|separator|>
  109. [109]
    Managing Excessive Daytime Sleepiness - Sleep Foundation
    Jan 16, 2024 · Graph showing up to 25% of Americans experience excessive daytime sleepiness. Previous studies showed. It is easy to confuse sleepiness with ...What Is Excessive Daytime... · Symptoms of Excessive...
  110. [110]
    Cognitive Behavioral Therapy for Insomnia (CBT-I): A Primer - PMC
    This intervention is typically comprised of two core components: Sleep Restriction Therapy (SRT) and Stimulus Control Therapy (SCT); and two adjunctive ...
  111. [111]
    Effects of cognitive behavioural therapy and bright light ... - NIH
    Apr 9, 2024 · A randomised controlled trial that examines the efficacy of CBT-I and CBT-I plus bright light therapy (BLT) in reducing insomnia severity, improving mood ...
  112. [112]
    Sleep Better With Healthy Lifestyle Habits
    Oct 7, 2025 · Exercise, diet, and stress can directly affect how well you sleep. Learn how making a few simple lifestyle changes during the day can help ...
  113. [113]
    Can a quick snooze help with energy and focus ... - Harvard Health
    Dec 4, 2024 · Power naps (10-30 minutes) can restore mental clarity, fight fatigue, increase alertness and focus, and boost productivity.Missing: diet somnolence
  114. [114]
    Better Sleep: 3 Simple Diet Tweaks | Johns Hopkins Medicine
    For better sleep, drink tart cherry juice, avoid spicy foods within 3 hours of bed, and eat complex carbs like whole-wheat toast.
  115. [115]
    Coping Strategies for Shift Work Disorder - Sleep Foundation
    Jul 25, 2025 · If you feel tired at the end of your shift, consider a brief nap in your car or a designated “nap room” at your workplace. Seek Help if Needed.
  116. [116]
    Treatment of central disorders of hypersomnolence
    The TF conducted a systematic review of the published scientific literature of U.S. Food & Drug Administration (FDA)–approved prescription medications and ...ABSTRACT · INTRODUCTION · METHODS · RECOMMENDATIONS
  117. [117]
    Armodafinil in the treatment of excessive sleepiness - PMC
    This review explores the evidence supporting the use of armodafinil to treat ES associated with OSA, SWD, and narcolepsy.
  118. [118]
    Methylphenidate - StatPearls - NCBI Bookshelf - NIH
    Mechanism of Action ... Given its effect on dopamine levels in the synapse, methylphenidate can provide neuroprotection in conditions like Parkinson disease, ...Continuing Education Activity · Mechanism of Action · Administration · Monitoring
  119. [119]
    Solriamfetol: Uses, Interactions, Mechanism of Action - DrugBank
    Mar 29, 2019 · The specific mechanism of action is unknown but it may be through its activity as a dopamine and norepinephrine reuptake inhibitor. Target ...
  120. [120]
    Pitolisant: Uses, Interactions, Mechanism of Action | DrugBank Online
    Pitolisant acts as a high-affinity competitive antagonist (Ki 0.16 nM) and as an inverse agonist (EC50 1.5 nM) at the human H3 receptor 1 and mediates its ...Identification · Pharmacology · Categories · References
  121. [121]
    Clinical considerations in the treatment of idiopathic hypersomnia
    To prevent potentially harmful drug–drug interactions, clinicians need to remain aware of other prescription and over-the-counter medications their patients may ...